{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:53:48Z","timestamp":1789595628816,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1097\/rlu.0000000000000757","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T10:41:24Z","timestamp":1425465684000},"page":"e308-e312","source":"Crossref","is-referenced-by-count":12,"title":["Optimized Protocol for 18F-Choline PET\/CT in Patients with Biochemically Relapsed Prostate Cancer"],"prefix":"10.1097","volume":"40","author":[{"given":"Sotirios","family":"Chondrogiannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Marzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Grassetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Rampin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Colletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Rubello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-30-20210204","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-30-20210204","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/01.ju.0000056901.95996.43","article-title":"Value of 11Ccholine-positron emission tomography for re-staging prostate cancer: a comparison with 18Ffluorodeoxyglucose-positron emission tomography.","volume":"169","author":"Picchio","year":"2003","journal-title":"J Urol"},{"key":"R3-30-20210204","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00259-007-0581-4","article-title":"The detection rate of (11)C choline-PETCT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.","volume":"35","author":"Krause","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-30-20210204","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11604-011-0570-1","article-title":"Role of 11C-choline positron emission tomographycomputed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation.","volume":"29","author":"Bertagna","year":"2011","journal-title":"Jpn J Radiol"},{"key":"R5-30-20210204","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00259-006-0150-2","article-title":"18FFluorocholine PETCT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.","volume":"33","author":"Cimitan","year":"2006","journal-title":"Eur J Med Mol Imaging"},{"key":"R6-30-20210204","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s11547-008-0263-8","article-title":"Role of whole body 18F-choline PETCT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.","volume":"113","author":"Pelosi","year":"2008","journal-title":"Radiol Med"},{"key":"R7-30-20210204","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/RLU.0b013e318266cc38","article-title":"Role of 18F-choline PETCT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.","volume":"38","author":"Marzola","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R8-30-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3413\/nukmed-0194","article-title":"Three-phase 18F-fluorocholine PETCT in the evaluation of prostate cancer recurrence.","volume":"48","author":"Steiner","year":"2009","journal-title":"Nuklearmedizin"},{"key":"R9-30-20210204","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PETCT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R10-30-20210204","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.urolonc.2010.08.008","article-title":"Imaging of prostate cancer with PETCT and radioactively labeled choline derivates.","volume":"31","author":"Krause","year":"2013","journal-title":"Urol Oncol"},{"key":"R11-30-20210204","first-page":"262","article-title":"Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.","volume":"47","author":"Kwee","year":"2006","journal-title":"J Nucl Med"},{"key":"R12-30-20210204","first-page":"43","article-title":"Positron emission tomographycomputed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA G 5ngml Mol Imaging Biol.","volume":"8","author":"Heinisch","year":"2006","journal-title":""},{"key":"R13-30-20210204","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1464-410X.2007.06772.x","article-title":"18F-Choline and 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate specific antigen values (G1 ngmL) after radical prostatectomy.","volume":"99","author":"Vees","year":"2007","journal-title":"BJU Int"},{"key":"R14-30-20210204","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00259-007-0686-9","article-title":"The value of 18F-choline PETCT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.","volume":"35","author":"Igerc","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-30-20210204","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00259-007-0552-9","article-title":"Evaluation of (18F)-choline PETCT for staging and restaging of prostate cancer.","volume":"35","author":"Husarik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-30-20210204","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1754-9485.2010.02178.x","article-title":"Pilot comparison of 18F-fluorocholine and 18F-fluorodeoxyglucose PETCT with conventional imaging in prostate cancer.","volume":"54","author":"Beauregard","year":"2010","journal-title":"J Med Imaging Radiat Oncol"},{"key":"R17-30-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2478\/v10019-010-0050-8","article-title":"Role of 18F-choline PETCT in evaluation of patients with prostate carcinoma.","volume":"45","author":"Hodolic","year":"2011","journal-title":"Radiol Oncol"},{"key":"R18-30-20210204","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00259-012-2083-2","article-title":"Clinical impact of 18F-choline PETCT in patients with recurrent prostate cancer.","volume":"39","author":"Soyka","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-30-20210204","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/MNM.0b013e328355990f","article-title":"(18F) Choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy, a preliminary study.","volume":"33","author":"Henninger","year":"2012","journal-title":"Nucl Med Comm"},{"key":"R20-30-20210204","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1464-410X.2012.11150.x","article-title":"18FFluoromethylcholine (FCH) positron emission tomographycomputed tomography (PETCT) for lymph node staging of prostate cancer: a prospective study of 210 patients.","volume":"110","author":"Poulsen","year":"2012","journal-title":"BJU Int"},{"key":"R21-30-20210204","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12149-012-0601-8","article-title":"Detection of recurrent prostate cancer with 18-fluorocholine PETCT in relation to PSA level at the time of imaging.","volume":"26","author":"Kwee","year":"2012","journal-title":"Ann Nucl Med"},{"key":"R22-30-20210204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1371\/journal.pone.0048430","article-title":"Dual-phase PET-CT to differentiate 18Ffluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer.","volume":"7","author":"Oprea-Lager","year":"2012","journal-title":"PLoS One"},{"key":"R23-30-20210204","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00259-011-1970-2","article-title":"Relationship between PSA kinetics and 18Ffluorocholine PETCT detection rates of recurrence in patients with prostate cancer after total prostatectomy.","volume":"39","author":"Graute","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-30-20210204","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1464-410X.2012.11123.x","article-title":"Combined 18F-fluorocholine and 18F-fluoride positron emission tomographycomputed tomography imaging for staging of high-risk prostate cancer.","volume":"110","author":"Kjolhede","year":"2012","journal-title":"BJU Int"},{"key":"R25-30-20210204","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2967\/jnumed.112.110148","article-title":"Impact of 18F-choline PETCT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.","volume":"54","author":"Beheshti","year":"2013","journal-title":"J Nucl Med"},{"key":"R26-30-20210204","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/RLU.0000000000000303","article-title":"(18)F-Choline PETCT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer.","volume":"39","author":"Calabria","year":"2014","journal-title":"Clin Nucl Med"},{"key":"R27-30-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PETCT for the diagnosis of recurrent prostate cancer.","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-30-20210204","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00259-013-2540-6","article-title":"First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PETCT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.","volume":"41","author":"Buchegger","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R29-30-20210204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-012-1354-4","article-title":"Predictive factors of 18F-choline PETCT in 170 patients with increasing PSA after primary radical treatment.","volume":"139","author":"Detti","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"R30-30-20210204","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/RLU.0b013e3182a23d37","article-title":"Diagnostic accuracy of 18F choline PETCT using time-of-flight reconstruction algorithm in prostate cancer patients with biochemical recurrence.","volume":"39","author":"Hausmann","year":"2014","journal-title":"Clin Nucl Med"},{"key":"R31-30-20210204","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/1947-2714.100994","article-title":"Optimising (18)F-choline PETCT acquisition protocol in prostate cancer patients.","volume":"4","author":"Massaro","year":"2012","journal-title":"N Am J Med Sci"},{"key":"R32-30-20210204","first-page":"110","article-title":"Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.","volume":"61","author":"DeGrado","year":"2001","journal-title":"Cancer Res"},{"key":"R33-30-20210204","first-page":"187","article-title":"Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.","volume":"43","author":"Hara","year":"2002","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000000757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:11:27Z","timestamp":1620972687000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201506000-00030"}},"subtitle":["Experiences on 250 Consecutive Cases"],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000000757","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}